North America Liquid Biopsy Market - 2024-2031
North America Liquid Biopsy Market reached US$ 1464.00 million in 2023 and is expected to reach US$ 5110.34 million by 2031, growing with a CAGR of 17.10% during the forecast period 2026-2031.
The North America Liquid Biopsy Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A North America Liquid Biopsy Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Circulating Biomarker
Both primary and secondary data sources have been used in the global North America Liquid Biopsy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The North America Liquid Biopsy Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A North America Liquid Biopsy Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Circulating Biomarker
- Circulating Tumor Cells*
- Circulating Tumor DNA (ctDNA)
- Cell-free DNA (cfDNA)
- Extracellular Vesicles
- Kits & Reagents*
- Instruments
- Services
- Cancer Applications*
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Prostate Cancer
- Liver Cancer
- Other
- Non-Cancer Applications
- Non-Invasive Prenatal Testing (NIPT)
- Organ Transplantations
- Infectious Disease Testing
- Multi-gene-parallel Analysis (NGS)*
- Single Gene Analysis (PCR Microarrays)
- Hospitals and Physician Laboratories*
- Research Centers
- Others
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global North America Liquid Biopsy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Circulating Biomarker
3.2. Snippet by Product & Services
3.3. Snippet by Application
3.4. Snippet by Technology
3.5. Snippet by End User
3.6. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Recent Advances in Liquid Biopsy Technologies for Cancer Biomarker Detection
4.1.1.2. Emerging Liquid Biopsy Techniques for Blood-based Detection of Tumor DNA
4.1.2. Restraints
4.1.2.1. Challenges in the Development of Liquid Biopsy Kits
4.1.3. Opportunity
4.1.3.1. Increasing Research Collaborations
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. RUSSIA-UKRAINE WAR ANALYSIS
8. BY CIRCULATING BIOMARKER
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarker
8.1.2. Market Attractiveness Index, By Circulating Biomarker
8.2. Circulating Tumor Cells*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Circulating Tumor DNA (ctDNA)
8.4. Cell-free DNA (cfDNA)
8.5. Extracellular Vesicles
9. BY PRODUCT & SERVICES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Services
9.1.2. Market Attractiveness Index, By Product & Services
9.2. Kits & Reagents*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Instruments
9.4. Services
10. BY APPLICATION
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.1.2. Market Attractiveness Index, By Application
10.2. Cancer Applications*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.2.3. Breast Cancer
10.2.4. Colorectal Cancer
10.2.5. Lung Cancer
10.2.6. Prostate Cancer
10.2.7. Liver Cancer
10.2.8. Other
10.3. Non-Cancer Applications
10.3.1. Non-Invasive Prenatal Testing (NIPT)
10.3.2. Organ Transplantations
10.3.3. Infectious Disease Testing
11. BY TECHNOLOGY
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.1.2. Market Attractiveness Index, By Technology
11.2. Multi-gene-parallel Analysis (NGS)*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Single Gene Analysis (PCR Microarrays)
12. BY END USER
12.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.2. Market Attractiveness Index, By End User
12.3. Hospitals and Physician Laboratories*
12.3.1. Introduction
12.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.4. Research Centers
12.5. Others
13. BY COUNTRY
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Circulating Biomarker
13.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
13.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
13.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
13.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
13.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
13.2.8.1. The U.S.
13.2.8.2. Canada
13.2.8.3. Mexico
14. COMPETITIVE LANDSCAPE
14.1. Competitive Scenario
14.2. Product Benchmarking
14.3. Company Share Analysis
14.4. Key Developments and Strategies
15. COMPANY PROFILES
15.1. Bio-Rad Laboratories*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. F. Hoffmann-La Roche AG
15.3. Exosome Sciences Inc.
15.4. Grail Inc
15.5. Guardant Health
15.6. Thermo Fisher Scientific Inc.
15.7. Inivata Ltd
15.8. Illumina Inc
15.9. LungLife AI Inc
15.10. Qiagen NV (*LIST NOT EXHAUSTIVE)
16. APPENDIX
16.1. About Us and Services
16.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Circulating Biomarker
3.2. Snippet by Product & Services
3.3. Snippet by Application
3.4. Snippet by Technology
3.5. Snippet by End User
3.6. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Recent Advances in Liquid Biopsy Technologies for Cancer Biomarker Detection
4.1.1.2. Emerging Liquid Biopsy Techniques for Blood-based Detection of Tumor DNA
4.1.2. Restraints
4.1.2.1. Challenges in the Development of Liquid Biopsy Kits
4.1.3. Opportunity
4.1.3.1. Increasing Research Collaborations
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. RUSSIA-UKRAINE WAR ANALYSIS
8. BY CIRCULATING BIOMARKER
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarker
8.1.2. Market Attractiveness Index, By Circulating Biomarker
8.2. Circulating Tumor Cells*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Circulating Tumor DNA (ctDNA)
8.4. Cell-free DNA (cfDNA)
8.5. Extracellular Vesicles
9. BY PRODUCT & SERVICES
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product & Services
9.1.2. Market Attractiveness Index, By Product & Services
9.2. Kits & Reagents*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Instruments
9.4. Services
10. BY APPLICATION
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.1.2. Market Attractiveness Index, By Application
10.2. Cancer Applications*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.2.3. Breast Cancer
10.2.4. Colorectal Cancer
10.2.5. Lung Cancer
10.2.6. Prostate Cancer
10.2.7. Liver Cancer
10.2.8. Other
10.3. Non-Cancer Applications
10.3.1. Non-Invasive Prenatal Testing (NIPT)
10.3.2. Organ Transplantations
10.3.3. Infectious Disease Testing
11. BY TECHNOLOGY
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.1.2. Market Attractiveness Index, By Technology
11.2. Multi-gene-parallel Analysis (NGS)*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Single Gene Analysis (PCR Microarrays)
12. BY END USER
12.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.2. Market Attractiveness Index, By End User
12.3. Hospitals and Physician Laboratories*
12.3.1. Introduction
12.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.4. Research Centers
12.5. Others
13. BY COUNTRY
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Circulating Biomarker
13.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
13.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
13.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
13.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
13.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
13.2.8.1. The U.S.
13.2.8.2. Canada
13.2.8.3. Mexico
14. COMPETITIVE LANDSCAPE
14.1. Competitive Scenario
14.2. Product Benchmarking
14.3. Company Share Analysis
14.4. Key Developments and Strategies
15. COMPANY PROFILES
15.1. Bio-Rad Laboratories*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. F. Hoffmann-La Roche AG
15.3. Exosome Sciences Inc.
15.4. Grail Inc
15.5. Guardant Health
15.6. Thermo Fisher Scientific Inc.
15.7. Inivata Ltd
15.8. Illumina Inc
15.9. LungLife AI Inc
15.10. Qiagen NV (*LIST NOT EXHAUSTIVE)
16. APPENDIX
16.1. About Us and Services
16.2. Contact Us
